DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Bucillamine

Bucillamine

  • Modifying Antirheumatic Drugs in Active Rheumatoid Arthritis: a Japan Phase 3 Trial (HARUKA)

    Modifying Antirheumatic Drugs in Active Rheumatoid Arthritis: a Japan Phase 3 Trial (HARUKA)

  • Study Protocol);

    Study Protocol);

  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

  • 24/3 Pag 121 Ok X WENDY

    24/3 Pag 121 Ok X WENDY

  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

  • Efficacy and Toxicity of Methotrexate (MTX)

    Efficacy and Toxicity of Methotrexate (MTX)

  • Alphabetical Listing of ATC Drugs & Codes

    Alphabetical Listing of ATC Drugs & Codes

  • Small Molecule DMARD Therapy and Its Position in RA Treatment

    Small Molecule DMARD Therapy and Its Position in RA Treatment

  • Mechanisms of Action of Second-Line Agents and Choice of Drugs in Combination Therapy

    Mechanisms of Action of Second-Line Agents and Choice of Drugs in Combination Therapy

  • Assessment Report

    Assessment Report

  • Serum Matrix Metalloproteinase-3 As Predictor of Joint Destruction in Rheumatoid Arthritis, Treated with Non-Biological Disease Modifying Anti-Rheumatic Drugs

    Serum Matrix Metalloproteinase-3 As Predictor of Joint Destruction in Rheumatoid Arthritis, Treated with Non-Biological Disease Modifying Anti-Rheumatic Drugs

  • WO 2012/175518 Al 27 December 2012 (27.12.2012) P O P C T

    WO 2012/175518 Al 27 December 2012 (27.12.2012) P O P C T

  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

  • Yellow Nail Syndrome in Rheumatoid Arthritis: an Aetiology Beyond Thiol Drugs Ajay Kumar Mishra1,*, Anu Anna George2 and Leni George2

    Yellow Nail Syndrome in Rheumatoid Arthritis: an Aetiology Beyond Thiol Drugs Ajay Kumar Mishra1,*, Anu Anna George2 and Leni George2

  • Journal of Bone Biology and Osteoporosis Iguratimod, a Synthetic Disease Modifying Anti- Rheumatic Drug (Sdmard), and Various Dmards Suppress Joint Destruction

    Journal of Bone Biology and Osteoporosis Iguratimod, a Synthetic Disease Modifying Anti- Rheumatic Drug (Sdmard), and Various Dmards Suppress Joint Destruction

  • WHO Pharmaceuticals

    WHO Pharmaceuticals

  • Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication

    Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication

  • KDIGO Clinical Practice Guideline for Glomerulonephritis

    KDIGO Clinical Practice Guideline for Glomerulonephritis

Top View
  • Study Protocol);
  • Australian Statistics on Medicines 2009
  • Wo 2007/044693 A2
  • Medications, Dry Mouth and Dental Caries Among Older People: a Longitudinal Study
  • Centre for Reviews and Dissemination
  • Mechanism of Action of the Disease
  • Systematic Review of Combination DMARD Therapy in Rheumatoid Arthritis Beusekom I. Van1, C. Maclean2, C.F. Allaart3, and F.C. Br
  • [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
  • Methotrexate and Oral Antirheumatic Drugs
  • A1298C Polymorphism 185 Abnormal Color Vision 87 Acetylcysteine 12
  • Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
  • Study of the Effect of Bucillamine on the Early and Late Phase of Hepatic Ischaemia Reperfusion Injury


© 2024 Docslib.org    Feedback